IP Library › Granted Patent US 12,558,316
Granted Patent B2
US 12,558,316 · App. 15/712,294 · Granted Feb 24, 2026

Methods and compositions for the treatment of epidermolysis bullosa

Inventor: Evangelos V. Badiavas (Coral Gables, FL)
Assignee: UNIVERSITY OF MIAMI
A61K9/127A61K9/0014A61K31/7088A61K35/16A61K35/22A61K35/28A61K38/1808A61K38/2033A61K38/204A61K38/21A61K38/39A61K38/45A61K45/06A61K47/46A61P17/00C12Y207/10002C12Y207/11024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,558,316
App. No.
15/712,294
Granted
Feb 24, 2026
Kind
B2
Abstract

The present invention provides compositions and methods for treating epidermolysis bullosa.

Claims (37)

1 . A method of treating epidermolysis bullosa in a human subject in need thereof comprising:

administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an enriched population of structurally and functionally intact heterogeneous population of vesicles collected from polyethylene glycol (PEG) precipitation from a biological fluid,

wherein the heterogeneous population of vesicles are combined with a pharmaceutically acceptable carrier or excipient:

wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles; wherein the heterogeneous population of vesicles comprise one or more bioactive agents comprising RNA, DNA, lipid, carbohydrate, metabolite, peptide, protein and combinations thereof;

wherein the biological fluid comprises mesenchymal stem cells;

wherein the method of treating results in lower levels of inflammation and higher levels of tissue regeneration than a method of administering microvesicles isolated by ultracentrifugation; and

wherein the method alleviates or reduces one or more symptoms of epidermolysis bullosa in the subject.

2 . The method of claim 1 , wherein the average molecular weight of the polyethylene glycol is about 6,000 Da, about 8,000 Da, about 10,000 Da or about 20,000 Da.

3 . The method of claim 1 , wherein the one or more symptoms of epidermolysis bullosa are any combination of thickened calluses, epidermal blistering, blistering of oral mucosa, thickened fingernails and/or toenails, sepsis, malnutrition, dehydration, electrolyte imbalance, obstructive airway complications, defective collagen VII expression, anemia, esophageal strictures, growth retardation, webbing or fusion of fingers and/or toes, malformation of teeth, microstomia and corneal abrasions.

4 . The method of claim 3 , wherein the epidermal blistering is of the hands, the feet, the elbows and/or the knees.

5 . The method of claim 1 , wherein treatment comprises increasing collagen VII expression in the subject and/or increasing expression of markers related to wound healing.

6 . The method of claim 1 , wherein the pharmaceutical composition is applied topically to the skin of the subject.

7 . The method of claim 1 , wherein the isolated heterogeneous population of vesicles range in size from 2 nm to 5000 nm.

8 . A method of treating dystrophic epidermolysis bullosa (DEB) in a human subject in need thereof comprising:

administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a heterogeneous population of vesicles in order to alleviate or reduce one or more symptoms of DEB in the subject,

wherein the heterogeneous population of vesicles are isolated by polyethylene glycol (PEG) precipitation from a biological fluid to obtain structurally and functionally intact isolated heterogeneous population of vesicles,

wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles;

wherein the biological fluid comprises mesenchymal stem cells,

wherein the isolated heterogeneous population of vesicles are combined with a pharmaceutically acceptable carrier or excipient.

9 . The method of claim 8 , wherein the dystrophic epidermolysis bullosa (DEB) is autosomal dominant (DDEB) or autosomal recessive (RDEB).

10 . The method of claim 8 , wherein the average molecular weight of the polyethylene glycol is about 6,000 Da, about 8,000 Da, about 10,000 Da or about 20,000 Da.

11 . The method of claim 8 , wherein the one or more symptoms of epidermolysis bullosa are selected from the group consisting of any combination of thickened calluses, epidermal blistering, blistering of oral mucosa, thickened fingernails and/or toenails, sepsis, malnutrition, dehydration, electrolyte imbalance, obstructive airway complications, defective collagen VII expression, anemia, esophageal strictures, growth retardation, webbing or fusion of fingers and/or toes, malformation of teeth, microstomia and corneal abrasions.

12 . The method of claim 11 , wherein the epidermal blistering is of the hands, the feet, the elbows and/or the knees.

13 . The method of claim 8 , wherein treatment comprises increasing collagen VII expression in the subject and/or increasing expression of markers related to wound healing.

14 . The method of claim 8 , wherein the pharmaceutical composition is applied topically to the skin of the subject.

15 . The method of claim 8 , wherein the isolated heterogeneous population of vesicles range in size from 2 nm to 5000 nm.

16 . A method of treating epidermolysis bullosa in a human subject in need thereof comprising:

(a) administering a therapeutically effective amount of a pharmaceutical composition comprising structurally and functionally intact isolated heterogeneous population of vesicles comprising one or more bioactive agents to the subject; and

(b) alleviating or reducing one or more symptoms of epidermolysis bullosa,

wherein the heterogeneous population of vesicles have been isolated by polyethylene glycol (PEG) precipitation from a biological fluid to obtain structurally and functionally intact isolated heterogeneous population of vesicles that are combined with a pharmaceutically acceptable carrier or excipient to produce the pharmaceutical composition prior to administration to the subject,

wherein the biological fluid comprises mesenchymal stem cells,

wherein the pharmaceutical composition contains isolated heterogeneous population of vesicles ranging in size from 2 nm to 5000 nm,

wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles,

wherein the isolated heterogeneous population of vesicles are less inflammatory than those produced using ultracentrifugation,

wherein the isolated heterogeneous population of vesicles are administered topically,

wherein the structurally and functionally intact isolated heterogeneous population of vesicles comprise one or more bioactive agents comprising RNA, DNA, lipid, carbohydrate, metabolite, peptide, protein and combinations thereof, and

wherein the method results in lower levels of inflammation and higher levels of tissue regeneration than a method of administering microvesicles isolated by ultracentrifugation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2018
From: BADIAVAS, EVANGELOS V.
To: UNIVERSITY OF MIAMI
Reel/Frame 047109/0722 →
Continuity (3)
Continuation In Part 14775382
Provisional Application 61778591 · Mar 13, 2013
Related Publication 20180104186A1 · Apr 19, 2018
References Cited (190)
US 6331298B1 · Ferguson et al. · 2001 [cited by applicant]
US 6509369B2 · Scott et al. · 2003 [cited by applicant]
US 6793945B2 · Bathurst et al. · 2004 [cited by applicant]
US 7807438B2 · Abrignani et al. · 2010 [cited by applicant]
US 7897356B2 · Klass et al. · 2011 [cited by applicant]
US 8021847B2 · Pietrzkowski · 2011 [cited by applicant]
US 8211653B2 · Klass et al. · 2012 [cited by applicant]
US 8216784B2 · Taylor et al. · 2012 [cited by applicant]
US 8278059B2 · Klass et al. · 2012 [cited by applicant]
US 8288172B2 · Ichim et al. · 2012 [cited by applicant]
US 8343485B2 · Pecora et al. · 2013 [cited by applicant]
US 8343725B2 · Croce et al. · 2013 [cited by applicant]
US 8349560B2 · Croce · 2013 [cited by applicant]
US 8349561B2 · Croce · 2013 [cited by applicant]
US 8349568B2 · Croce et al. · 2013 [cited by applicant]
US 8349574B2 · Bates et al. · 2013 [cited by applicant]
US 8901284B2 · Vlassov et al. · 2014 [cited by applicant]
US 9005888B2 · Antes et al. · 2015 [cited by applicant]
US 9066971B2 · Gho et al. · 2015 [cited by applicant]
US 9828603B2 · Marban et al. · 2017 [cited by applicant]
US 9856477B2 · Lotvall et al. · 2018 [cited by applicant]
US 10500231B2 · Badiavas et al. · 2019 [cited by applicant]
US 11730768B2 · Badiavas et al. · 2023 [cited by applicant]
US 20030198642A1 · Geuze et al. · 2003 [cited by applicant]
US 20040132729A1 · Salituro et al. · 2004 [cited by applicant]
US 20040171623A1 · Reynolds et al. · 2004 [cited by applicant]
US 20040209901A1 · Adams et al. · 2004 [cited by applicant]
US 20040220393A1 · Ward et al. · 2004 [cited by applicant]
US 20060116321A1 · Robbins et al. · 2006 [cited by applicant]
US 20080268429A1 · Pietrzkowski · 2008 [cited by applicant]
US 20090292109A1 · Gronke et al. · 2009 [cited by applicant]
US 20100047335A1 · Egea et al. · 2010 [cited by applicant]
US 20100104542A1 · Austen, Jr. · 2010 [cited by applicant]
US 20100184046A1 · Klass et al. · 2010 [cited by applicant]
US 20100189744A1 · Bryan et al. · 2010 [cited by applicant]
US 20100196426A1 · Skog et al. · 2010 [cited by applicant]
US 20100255514A1 · Rak et al. · 2010 [cited by applicant]
US 20110003008A1 · Lim · 2011 [cited by applicant]
US 20110195426A1 · Russo et al. · 2011 [cited by applicant]
US 20120053976A1 · Hu et al. · 2012 [cited by applicant]
US 20120058492A1 · Lozupone et al. · 2012 [cited by applicant]
US 20120070858A1 · Contreras et al. · 2012 [cited by applicant]
US 20120093885A1 · Sahoo et al. · 2012 [cited by applicant]
US 20120171290A1 · Coursaget et al. · 2012 [cited by applicant]
US 20120214151A1 · Newman et al. · 2012 [cited by applicant]
US 20120238467A1 · Taylor et al. · 2012 [cited by applicant]
US 20120309041A1 · Timmers et al. · 2012 [cited by applicant]
US 20120315324A1 · Zhang · 2012 [cited by applicant]
US 20130337440A1 · Antes · 2013 [cited by examiner]
US 20160184363A1 · Badiavas et al. · 2016 [cited by applicant]
US 20170258845A1 · Lim · 2017 [cited by examiner]
US 20190133922A1 · Kang et al. · 2019 [cited by applicant]
US 20200163999A1 · Badiavas et al. · 2020 [cited by applicant]
US 20220072049A1 · Badiavas et al. · 2022 [cited by applicant]
US 20230364150A1 · Badiavas et al. · 2023 [cited by applicant]
CN 101854941A · 2010 [cited by applicant]
CN 105209881A · 2015 [cited by applicant]
EP 1780267A2 · 2007 [cited by applicant]
EP 2604288A1 · 2013 [cited by applicant]
EP 2687219A1 · 2014 [cited by applicant]
EP 2972193A1 · 2016 [cited by applicant]
EP 3677271A1 · 2020 [cited by applicant]
EP 3684336A1 · 2020 [cited by applicant]
JP 2010514433A · 2010 [cited by applicant]
JP 2011513217A · 2011 [cited by applicant]
JP 2013537538A · 2013 [cited by applicant]
JP 2016518109A · 2016 [cited by applicant]
JP 2017526723A · 2017 [cited by applicant]
JP 2019195331A · 2019 [cited by applicant]
WO 2004014954A1 · 2004 [cited by applicant]
WO 2006007529A2 · 2006 [cited by applicant]
WO 2007103572A2 · 2007 [cited by applicant]
WO 2007126386A1 · 2007 [cited by applicant]
WO WO2008080989A1 · 2008 [cited by applicant]
WO WO2009050742A1 · 2009 [cited by applicant]
WO 2009092386A2 · 2009 [cited by applicant]
WO WO2009087361A1 · 2009 [cited by applicant]
WO WO2009105044A1 · 2009 [cited by third party]
WO 2009115561A1 · 2009 [cited by applicant]
WO 2010119256A1 · 2010 [cited by applicant]
WO 2011000551A1 · 2011 [cited by applicant]
WO 2012002760A2 · 2012 [cited by applicant]
WO WO2012020307A2 · 2012 [cited by third party]
WO 2012108842A1 · 2012 [cited by applicant]
WO 2012110099A1 · 2012 [cited by applicant]
WO 2012110253A2 · 2012 [cited by applicant]
WO 2012126531A1 · 2012 [cited by applicant]
WO 2012135844A2 · 2012 [cited by applicant]
WO 2012169970A1 · 2012 [cited by applicant]
WO WO2013014669A1 · 2013 [cited by applicant]
WO WO2013014691A1 · 2013 [cited by applicant]
WO 2013022786A2 · 2013 [cited by applicant]
WO WO2017122095A1 · 2013 [cited by applicant]
WO WO2013188832A1 · 2013 [cited by third party]
WO WO2014159662A1 · 2014 [cited by applicant]
WO WO2015138878A1 · 2015 [cited by applicant]
WO WO2016043654A1 · 2016 [cited by third party]
WO WO2016172598A1 · 2016 [cited by applicant]
WO WO2016196173A1 · 2016 [cited by applicant]
WO WO2017123022A1 · 2017 [cited by applicant]
WO WO2019060719A1 · 2019 [cited by applicant]
WO WO2019231562A1 · 2019 [cited by applicant]
WO WO2012053976A1 · 2020 [cited by applicant]
SystemBiosciences Exoquick-TC Exosome Precipitation Solution pp. 1-10, 2011 (Year: 2011). [cited by examiner]
Bruno (Immunology Letters 168 (2015) 154-158), (Year: 2015). [cited by examiner]
El-Darouti (Dermatologic Therapy, 20: 1-5, 2016). (Year: 2016). [cited by examiner]
Katsuda et al. “The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles” (Jan. 2013), Proteomics, vol. 13: 1637-1653. (Year: 2013). [cited by examiner]
Gimona et al. (2017) “Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use,” International Journal of Molecular Sciences, 18(6): 19 pages. [cited by applicant]
McBride et al. (2017) “Extracellular Vesicles as Biomarkers and Therapeutics in Dermatology: A Focus on Exosomes,” Journal of Investigative Dermatology, 137(8): 1622-1629. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/05223, mailing date Jan. 4, 2019. [cited by applicant]
U.S. Appl. No. 14/775,382 / 2016/0184363 / U.S. Pat. No. 10,500,231, filed Mar. 12, 2014 / Jun. 30, 2016 / Dec. 10, 2019, Evangelos V. Badiavas. [cited by applicant]
U.S. Appl. No. 16/668,851, filed Oct. 30, 2019, Evangelos V. Badiavas. [cited by applicant]
Ludwig et al., “Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales,” Journal of Ext… [cited by applicant]
Lasser et al., “Isolation and Characterization of RNA-Containing Exosomes”, Journal of Visualized Experiments, Jan. 9, 2012, pp. 1-6. [cited by applicant]
Chen et al., “Cardiac progenitor-derived Exosomes protect ischemic myocardium from acute ischemia/reperfusion injury”, Biochem Biophys Res Commun, Feb. 15, 2013, vol. 431, No. 3, pp. 566-571. [cited by applicant]
Extended European Search Report in European Patent Application No. 1921541.7, mailed Jun. 9, 2020, 15 pages. [cited by applicant]
Taylor et al., “Exosome Isolation for Proteomic Analyses and RNA Profiling”, Methods in Molecular Biology, Feb. 2011, vol. 728, pp. 235-246. [cited by applicant]
Albarran Y Carvajal et al. (2007) “MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study,” Biodrugs. 21(1):47-59. [cited by applicant]
Andreu et al. (Jun. 20, 2016) “Comparative Analysis of EV Isolation Procedures for miRNAs Detection in Serum Samples,” J. Extracell. Vesicles. 5:31655. [cited by applicant]
Grenier et al. (1987) “Functional characterization of extracellular vesicles produced by Bacteroides gingivalis,” Infection and Immunity. 55(1):111-117. [cited by applicant]
Merz et al. (2010) “Biochemical and Morphological Properties of Hepatitis C Virus Particles and Determination of Their Lipidome,” J. Bol. Chem. 286(4):3018-3032. [cited by applicant]
Mori et al. (2008) “Human herpesvirus-6 induces MVB formation, and virus egress occurs by an exosomal release pathway,” Traffic. 9:1728-1742. [cited by applicant]
Radhakrishnan et al. (2010) “Protein Analysis of Purified Respiratory Syncytial Virus Particles Reveals an Important Role for Heat Shock Protein 90 in Virus Particle Assembly,” Mol. Cell. Proteomics. 9(9):1829-1848. [cited by applicant]
Raposo et al. (Feb. 18, 2013) “Extracellular vesicles: Exosomes, microvesicles, and friends,” J. Cell. Biology. 4:373-383. [cited by applicant]
System Biosciences (2013) “User Manual: ExoQuick-TC(TM) Exosome Precipitation Solution,” Catalog No. EXOTCxxA-1. System Biosciences (SBI). Accessible on the Internet at URL: https://www.systembio.com/downloads/Manual_Ex… [cited by applicant]
Venugopal et al. (2010) “Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man,” Arch. Dermatol. 14… [cited by applicant]
Villa et al. (2006) “High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up,” Br. J. Cancer. 95:1459-1466. [cited by applicant]
Zoller (2009) “Tetraspanins: push and pull in suppressing and promoting metastasis,” Nat. Rev. Cancer. 9(1):40-55. [cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/JS2014/024629, mailed Jul. 3, 2014. [cited by applicant]
Bartholomew et al. (2009) “Mesenchymal stem cells in the induction of transplantation tolerance,” Transplantation. 87:S55-7. [cited by applicant]
Breau et al. (2006) “Inadequate statistical power of negative clinical trials in urological literature,” The Journal of Urology. 176:263-6. [cited by applicant]
Bruno et al. (Jun. 15, 2015) “The secretome of mesenchymal stromal cells: Role of extracellular vesicles in Immunomodulation,” Immunology Letters. 168:154-8. [cited by applicant]
Chen et al. (Aug. 2016) “Immunomodulatory effects of mesenchymal stromal cells-derived exosome,” Immunologic Research. 64:831-40. [cited by applicant]
El-Darouti et al. (Oct. 5, 2015) “Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial,” Dermatol. Ther. 29:96-100. [cited by applicant]
Ichihara (2010) “An appraisal of statistical procedures used in derivation of reference intervals,” Clinical Chemistry and Laboratory Medicine. 48:1537-51. [cited by applicant]
Haydek et al. (Aug. 10, 2017) “Validation and Banding of the ItchyQuant: A Self-Report Itch Severity Scale,” J. Invest. Dermatol. 137:57-61. [cited by applicant]
Jones et al. (1995) “Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain,” J. Invest. Dermatol. 104:231… [cited by applicant]
Lapiere et al. (1993) “Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa,” J. Clin. Invest. 92:1831-9. [cited by applicant]
Li et al. (Apr. 27, 2016) “Exosome Derived From Human Umbilical Cord Mesenchymal Stem Cell Mediates MiR-181c Attenuating Burn-induced Excessive Inflammation,” EBioMedicine. 8:72-82. [cited by applicant]
McBride et al. (Mar. 15, 2017) “Transgenic expression of a canonical Wnt inhibitor, kallistatin, is associated with decreased circulating CD19+ B lymphocytes in the peripheral blood,” International Journal of Hematology… [cited by applicant]
Palazzi et al. (2000) “Inherited dystrophic epidermolysis bullosa in inbred dogs: A spontaneous animal model for somatic gene therapy,” J. Invest. Dermatol. 115:135-7. [cited by applicant]
Petrof et al. (Apr. 23, 2015) “Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa,” J. Invest. Dermatol. 135:2319-21. [cited by applicant]
Pfendner et al. (2001) “Epidermolysis bullosa carrier frequencies in the US population,” J. Invest. Dermatol. 116:483-4. [cited by applicant]
Riazifar et al. (Oct. 28, 2016) “Stem Cell Extracellular Vesicles: Extended Messages of Regeneration,” Annu. Rev. Pharmacol. Toxicol. 57:125-54. [cited by applicant]
Shabbir et al. (May 20, 2015) “Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro,” Stem Cells Dev. 24(14):1635-47. [cited by applicant]
Siegel et al. (2009) “The immunosuppressive properties of mesenchymal stem cells,” Transplantation. 87:S45-9. [cited by applicant]
South et al. (Jun. 2016) “Type VII Collagen Replacement Therapy in Recessive Dystrophic Epidermolysis Bullosa—How Much, How Often?” J. Invest. Dermatol. 136:1079-81. [cited by applicant]
Sundin et al. (2009) “HSCT recipients have specific tolerance to MSC but not to the MSC donor,” J. Immunother. 32:755-64. [cited by applicant]
Wagner et al. (2010) “Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa,” The New England Journal of Medicine. 363:629-39. [cited by applicant]
Woodley et al. (Jul. 10, 2017) “Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients,” J. Clin. Invest. 127(8):3028-3038. [cited by applicant]
Woodley et al. (Nov. 8, 2013) “De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa,” J. Invest. Dermatol. 134:1138-40. [cited by applicant]
Japanese Patent Application No. 2016-501590, Official Action Summary dated Mar. 13, 2018, 1 page. [cited by applicant]
Japanese Patent Application No. 2016-501590, English Translation of the Office Action dated Mar. 13, 2018, 7 pp. [cited by applicant]
Vlassov et al., “Review, Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials”, Biochemica et Biophysica Acta 1820, 2012, pp. 940-948. [cited by applicant]
U.S. Appl. No. 14/775,382 2016/0184363 U.S. Pat. No. 10,500,231, filed Sep. 11, 2015 Jun. 30, 2016 Dec. 10, 2019, Evangelos V. Badiavas. [cited by applicant]
U.S. Appl. No. 15/712,294 2018/0104186, filed Sep. 22, 2017 Apr. 19, 2018, Evangelos V. Badiavas. [cited by applicant]
U.S. Appl. No. 16/668,851 2020/0163999, filed Oct. 30, 2019 May 28, 2020, Evangelos V. Badiavas. [cited by applicant]
Kim et al., “Identification and characterization of stem cell secretome-based recombinant proteins for wound healing applications”, Fromteirs in Bioengineering and Biotechnology, Jul. 22, 2022, 10.3389/fbioe.2022.954682. [cited by applicant]
Lee et al., “Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy”, Human Molecular Genetics, 2012, 21(1):R125-R134. [cited by applicant]
U.S. Appl. No. 14/775,382 2016/0184363 U.S. Pat. No. 10,500,231, filed Sep. 11, 2015 Jun. 30, 2016 Dec. 10, 2019, Evangelos V. Badiavas, Method for Isolation and Purification of Microvesicles from Cell Culture Supernata… [cited by applicant]
U.S. Appl. No. 15/712,294 2018/0104186, filed Sep. 22, 2017 Apr. 19, 2018, Evangelos V. Badiavas, Methods and Compositions for the Treatment of Epidermolysis Bullosa. [cited by applicant]
U.S. Appl. No. 16/668,851 2020/0163999, filed Oct. 30, 2019 May 28, 2020, Evangelos V. Badiavas, Method for Isolation and Purification of Microvesicles from Cell Culture Supernatants and Biological Fluids. [cited by applicant]
U.S. Appl. No. 18/332,063, filed Jun. 9, 2023, Evangelos V. Badiavas, Method for Isolation and Purification of Microvesicles From Cell Culture Supernatants and Biological Fluids. [cited by applicant]
[1P1013] (EV), EV(Extracellular vesicles), exosome, Abstracts of the Annual Meeting of the Japanese Biochemical Society and the Annual Meeting of the Molecular Biology Society of Japan, 2015, 88th. [cited by applicant]
BioCat GmbH, “Exosome Isolation”, published online Aug. 20, 2011, retrieved from url: https://www.biocat.com/cell-biology/exosomes/exosome-isolation. [cited by applicant]
Bray et al., “Extracellular Vesicles as Therapeutic Tools for the Treatment of Chronic Wounds”, Pharmaceutics, 2021, 13(1543): 1-25. [cited by applicant]
Chen et al., “Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing”, PLoS One, Feb. 2008, 3(4): e1886. [cited by applicant]
Heo et al., “Tumor Necrosis Factor-α-Activated Human Adipose Tissue-Derived Mesenchymal Stem Cells Accelerate Cutaneous Wound Healing through Paracrine Mechanisms”, Journal of Investigative Dermatology, Jul. 2011, 131(7… [cited by applicant]
Lai et al., “Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury”, Stem Cell Research, May 2010, 4(3): 214-222. [cited by applicant]
Lai et al., “Mesenchymal stem cell exosomes”, Seminars in Cell & Developmental Biology, Apr. 2015, 40: 828-88. [cited by applicant]
Lee et al., “Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension”, Circulation, Nov. 27, 2012, 126(22): 2601-2611. [cited by applicant]
Vishnubhatla et al., “The Development of Stem Cell-derived Exosomes as a Cell-free Regenerative Medicine”, J Circ Biomark., 2014, 3(2): 1-14. [cited by applicant]
Yew et al., “Enhancement of Wound Healing by Human Multipotent Stromal Cell Conditioned Medium: The Paracrine Factors and p38 MAPK Activation”, Cell Transplantation, 2011, 20: 693-706. [cited by applicant]
Extended European Search Report for European Patent Application No. 18859166.3, mailed May 6, 2021, 8 pages. [cited by applicant]
Extended European Search Report received for European Patent Application No. 14774189.6, mailed on Aug. 4, 2016. [cited by applicant]
Ha et al., “Exosomes as Therapeutic Drug Carriers and Delivery Vehicles Across Biological Membranes: Current Perspectives and Future Challenges”, Acta Pharmaceutica Sinica B, 2016, 6(4): 287-296. [cited by applicant]
International Preliminary Report on Patentability for PCT International Patent Application No. PCT/US2018/052213, dated Mar. 24, 2020, 9 pages. [cited by applicant]
Katsuda et al. “The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles”, Jan. 2013, Proteomics, 13(10-11): 1637-1653. [cited by applicant]
Sun et al., “Exosomes Are Endogenous Nanoparticles that can deliver biological information between cells”, Advanced Drug Delivery Reviews, 2013, 65: 342-347. [cited by applicant]
System Biosciences Exoquick-TC Exosome Precipitation Solution, 2011, pp. 1-10. [cited by applicant]
Vlassov et al., “Review, Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials”, Biochemica et Biophysica Acta (BBA), 2012, 1820(7): 940-948. [cited by applicant]
Collino et al., “Exosome and Microvesicle-Enriched Fractions Isolated from Mesenchymal Stem Cells by Gradient Separation Showed Different Molecular Signatures and Functions on Renal Tubular Epithelial Cells”, Stem Cell … [cited by applicant]
Colombo et al., “Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles”, Annu. Rev. Cell Dev. Biol., 2014, 30: 255-289. Epub Aug. 21, 2014. [cited by applicant]
Han et al., “Apoptotic extracellular vesicles: mechanisms, applications, and therapeutic potential”, Med-X, Dec. 16, 2024, 2: 27. [cited by applicant]
Ma et al., “Apoptotic extracellular vesicles are metabolized regulators nurturing the skin and hair”, Bioactive Mater., May 11, 2022, 19: 626-641. eCollection Jan. 2023. [cited by applicant]
McBride et al., “Bone Marrow Mesenchymal Stem Cell-Derived CD63+ Exosomes Transport Wnt3a Exteriorly and Enhance Dermal Fibroblast Proliferation, Migration, and Angiogenesis In Vitro”, Stem Cells Dev., Oct. 1, 2017, 26(… [cited by applicant]
Papait et al., “Comparison of EV-free fraction, EVs, and total secretome of amniotic mesenchymal stromal cells for their immunomodulatory potential: a translational perspective”, Frontiers in Immunology, Aug. 16, 2022, … [cited by applicant]
Wolf et al., “A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation”, J. Extracell. Vesicles, Apr. 2022, 11(4): e12207. [cited by applicant]
Zhou et al., “Apoptotic bodies for advanced drug delivery and therapy”, J. Controlled Release, Nov. 2022, 351: 394-406. Epub Sep. 27, 2022. [cited by applicant]
L Chen et al., Cardiac progenitor-derived Exosomes protect ischemic myocardium from acute ischemia/reperfusion injury, Biochem. Biophys. Res. Commun., 431(3):566-71, (Feb. 15, 2013). [cited by third party]